When is indomethacin preferred over colchicine, and vice versa, for treating acute gout flares?

When to Give Indomethacin vs Colchicine

For acute gout flares, choose based on patient-specific contraindications rather than efficacy, as both are equally effective—but avoid indomethacin specifically since it offers no advantage over other NSAIDs and carries higher cardiovascular risk. 1

Treatment Selection Algorithm

For Acute Gout Flares

First-line choice: Corticosteroids (if no contraindications) because they are generally safer and lower cost than both NSAIDs and colchicine 1. Prednisolone 35 mg for 5 days is effective.

Second-line options (choose based on contraindications):

• Colchicine (low-dose: 1.2 mg followed by 0.6 mg one hour later, max 1.8 mg over one hour) 1, 2

  • Contraindicated in: Renal impairment (CrCl <30), hepatic impairment, patients on strong CYP3A4 inhibitors (clarithromycin, ketoconazole, ritonavir) or P-glycoprotein inhibitors 1, 2
  • Advantages: Lower cardiovascular risk than NSAIDs 3
  • Disadvantages: More expensive than NSAIDs, GI side effects (diarrhea, nausea, vomiting) 1

• NSAIDs (any NSAID except indomethacin) - naproxen or ibuprofen preferred

  • Contraindicated in: Renal disease (CKD stage ≥3), heart failure, cirrhosis, history of GI bleeding, anticoagulant use 1
  • Critical point: Indomethacin has no superior efficacy over other NSAIDs despite being traditionally considered "first-line" 1. Recent evidence shows NSAIDs increase cardiovascular events compared to colchicine (HR 1.56 for MACE) 3

For Gout Flare Prophylaxis (when starting urate-lowering therapy)

Strongly recommended to use prophylaxis for 3-6 months when initiating allopurinol or other urate-lowering therapy 4.

Choice hierarchy:

1. Colchicine 0.6 mg once or twice daily (max 1.2 mg/day) 2

   • Preferred due to lower cardiovascular risk than NSAIDs 3
   • Adjust dose in renal impairment: 0.3 mg daily if CrCl 30-59 mL/min 2, 5

2. NSAIDs - only if colchicine contraindicated

   • Associated with 50% higher risk of MACE compared to colchicine (rate difference 38.8 per 1000 person-years) 3
   • Higher risk of MI (HR 1.93) compared to no prophylaxis 3

3. Prednisone/prednisolone - if both above contraindicated 4

Key Clinical Pitfalls

Do NOT use indomethacin specifically - despite historical preference, moderate-quality evidence shows no difference between NSAIDs, and indomethacin carries the same cardiovascular risks as other NSAIDs without added benefit 1.

Avoid NSAIDs for prophylaxis when possible - the 2025 target trial emulation demonstrates significantly higher cardiovascular events with NSAID prophylaxis versus colchicine (HR 1.56 for MACE, HR 2.50 for cardiovascular death) 3.

Colchicine dosing errors are common - use LOW-DOSE colchicine (1.2 mg then 0.6 mg one hour later) for acute flares, NOT the outdated high-dose hourly regimen, which causes more GI toxicity without added efficacy 1.

Drug interactions with colchicine are dangerous - fatal toxicity reported with strong CYP3A4 inhibitors like clarithromycin. If patient is on these medications, reduce colchicine dose by 50-75% or avoid entirely 2.

Evidence Quality Note

The 2017 ACP guidelines 1 provide high-quality evidence (strong recommendations) that corticosteroids, NSAIDs, and colchicine are all effective for acute gout, with choice driven by safety profile rather than efficacy. The 2020 ACR guidelines 4 strongly recommend prophylaxis when starting urate-lowering therapy. The most recent 2025 cardiovascular safety data 3 shifts the risk-benefit calculation toward colchicine over NSAIDs for prophylaxis.